Brief Article
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 21, 2013; 19(31): 5111-5117
Published online Aug 21, 2013. doi: 10.3748/wjg.v19.i31.5111
Diagnostic accuracy of a new point-of-care screening assay for celiac disease
Faiza Benkebil, Christophe Combescure, Silvia I Anghel, Cécile Besson Duvanel, Michela G Schäppi
Faiza Benkebil, Vidymed, 1007 Lausanne, Switzerland
Christophe Combescure, CRC and Division of Clinical Epidemiology, Department of Health and Community Medicine, University of Geneva and University Hospitals of Geneva, 1007 Geneva, Switzerland
Silvia I Anghel, R and D Department, Augurix, BioArk, 1870 Monthey, Switzerland
Cécile Besson Duvanel, Scientific Officer, Augurix, BioArk, 1870 Monthey, Switzerland
Michela G Schäppi, Pediatric Gastroenterology Unit, Pediatrics Department, Geneva University Hospitals, 1211 Geneva, Switzerland
Author contributions: Benkebil F designed the study and performed the research; Combescure C performed the statistical analysis and wrote the paper; Anghel SI performed the data analysis and wrote the paper; Besson Duvanel C designed the study and wrote the paper; Schäppi MG designed the study, performed the research, and wrote the paper.
Supported by the Swiss Celiac Association, Association Romande de Coeliakie, No. ME 8309 awarded to Schäppi MG
Correspondence to: Michela G Schäppi, MD, PhD, Clinique des Grangettes 7, Chemin des Grangettes, 1224 Chêne-Bougeries, Switzerland.
Telephone: +41-22-3050578 Fax: +41-22-3050579
Received: January 29, 2013
Revised: April 23, 2013
Accepted: May 8, 2013
Published online: August 21, 2013
Core Tip

Core tip: The aim of the present study was to evaluate the clinical accuracy of a new point-of-care device that is based on deamidated gliadin peptides (DGP) for diagnosis of celiac disease (CD). One-hundred-and-twelve patients with clinical symptoms suggestive of CD and/or first-degree relatives of CD patients, and patients with confirmed CD on a gluten-free diet, were prospectively enrolled in the study. The actual CD diagnosis had been based on serum-positive immunoglobulin A anti-tissue transglutaminase results by enzyme-linked immunosorbent assay and on biopsy findings. Overall evaluation shows that the new DGP-based rapid point-of-care test is an excellent screening tool for high-risk populations.